LDL receptors and their role in targeted therapy for glioma: a review
- PMID: 33609780
- DOI: 10.1016/j.drudis.2021.02.008
LDL receptors and their role in targeted therapy for glioma: a review
Abstract
Gliomas are highly lethal forms of cancers occurring in the brain. Delivering the drugs into the brain is a major challenge to the treatment of gliomas because of the highly selectively permeable blood-brain barrier (BBB). Tapping the potential of receptor-mediated drug delivery systems using targeted nanoparticles (NPs) is a sought-after step forward toward successful glioma treatment. Several receptors are the focus of research for application in drug delivery. Low-density lipoprotein receptors (LDLR) are abundantly expressed in both healthy brains and diseased brains with a disrupted BBB. In this review, we discuss the LDLR and the types of NPs that have been used to target the brain via this receptor.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Similar articles
-
Enhanced blood-brain barrier penetration and glioma therapy mediated by T7 peptide-modified low-density lipoprotein particles.Drug Deliv. 2018 Nov;25(1):1652-1663. doi: 10.1080/10717544.2018.1494223. Drug Deliv. 2018. PMID: 30394123 Free PMC article.
-
LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma.Biomaterials. 2013 Dec;34(36):9171-82. doi: 10.1016/j.biomaterials.2013.08.039. Epub 2013 Sep 3. Biomaterials. 2013. PMID: 24008043
-
Peptide-functionalized and high drug loaded novel nanoparticles as dual-targeting drug delivery system for modulated and controlled release of paclitaxel to brain glioma.Int J Pharm. 2018 Dec 20;553(1-2):169-185. doi: 10.1016/j.ijpharm.2018.10.022. Epub 2018 Oct 12. Int J Pharm. 2018. PMID: 30321641
-
Targeted brain delivery nanoparticles for malignant gliomas.Nanomedicine (Lond). 2017 Jan;12(1):59-72. doi: 10.2217/nnm-2016-0307. Epub 2016 Nov 23. Nanomedicine (Lond). 2017. PMID: 27876436 Review.
-
The blood-brain/tumor barriers: challenges and chances for malignant gliomas targeted drug delivery.Curr Pharm Biotechnol. 2012 Sep;13(12):2380-7. doi: 10.2174/138920112803341798. Curr Pharm Biotechnol. 2012. PMID: 23016643 Review.
Cited by
-
Counteracting Immunosenescence-Which Therapeutic Strategies Are Promising?Biomolecules. 2023 Jul 6;13(7):1085. doi: 10.3390/biom13071085. Biomolecules. 2023. PMID: 37509121 Free PMC article. Review.
-
Uptake of lipid core nanoparticles by fragments of tissues collected during cerebral tumor excision surgeries: hypotheses for use in drug targeting therapy.J Neurooncol. 2022 Jul;158(3):413-421. doi: 10.1007/s11060-022-04028-1. Epub 2022 May 25. J Neurooncol. 2022. PMID: 35612697
-
Molecular Determinants for Photodynamic Therapy Resistance and Improved Photosensitizer Delivery in Glioma.Int J Mol Sci. 2024 Aug 9;25(16):8708. doi: 10.3390/ijms25168708. Int J Mol Sci. 2024. PMID: 39201395 Free PMC article. Review.
-
Probing the affinity of noble metal nanoparticles to the segments of the SARS-CoV-2 spike protein.iScience. 2023 Mar 17;26(3):106110. doi: 10.1016/j.isci.2023.106110. Epub 2023 Feb 4. iScience. 2023. PMID: 36776935 Free PMC article.
-
How Precise are Nanomedicines in Overcoming the Blood-Brain Barrier? A Comprehensive Review of the Literature.Int J Nanomedicine. 2024 Mar 8;19:2441-2467. doi: 10.2147/IJN.S442520. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38482521 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical